CAJ | 학술논문

目的探讨CT引导下经皮穿刺微波凝固治疗(PMCT )联合131 I肿瘤细胞核人鼠嵌合单克隆抗体注射液(131I-chTNT)治疗局部中晚期老年非小细胞肺癌(NSCLC)的临床疗效及安全性.方法 78例Ⅲb~ Ⅳ期不可手术切除的老年NSCLC患者分成2组 :对照组(37例)行化疗联合放疗 ;观察组(41例)行微波凝固联合131 I-chTNT放射免疫治疗.对比分析2组患者的临床疗效、生存质量、不良反应发生率及生存率.结果对照组和观察组患者的治疗有效率分别为46% 和68% ,差异有统计学意义( P<0. 05 );对照组 K PS评分改善率为54% ,观察组为78% ,差异有统计学意义( P<0. 05 );对照组与观察组1年生存率分别为49% 和59% ,中位生存时间分别为340 d和389 d ,差异无统计学意义( P>0. 05 ).观察组的不良反应发生率明显比对照组低 ,差异有统计学意义(P<0.05).结论微波凝固联合131 I-chTNT放射免疫综合治疗不可手术切除的中晚期老年 NSCLC短期疗效优于同期放化疗方案 ,不良反应低 ,患者耐受良好 ,是一种安全、有效的治疗方法.
목적 탐토CT인도하경피천자미파응고치료(PMCT )연합131 I종류세포핵인서감합단극륭항체주사액(131I-chTNT)치료국부중만기노년비소세포폐암(NSCLC)적림상료효급안전성.방법 78례Ⅲb~ Ⅳ기불가수술절제적노년NSCLC환자분성2조 :대조조(37례)행화료연합방료 ;관찰조(41례)행미파응고연합131 I-chTNT방사면역치료.대비분석2조환자적림상료효、생존질량、불량반응발생솔급생존솔.결과 대조조화관찰조환자적치료유효솔분별위46% 화68% ,차이유통계학의의( P<0. 05 );대조조 K PS평분개선솔위54% ,관찰조위78% ,차이유통계학의의( P<0. 05 );대조조여관찰조1년생존솔분별위49% 화59% ,중위생존시간분별위340 d화389 d ,차이무통계학의의( P>0. 05 ).관찰조적불량반응발생솔명현비대조조저 ,차이유통계학의의(P<0.05).결론 미파응고연합131 I-chTNT방사면역종합치료불가수술절제적중만기노년 NSCLC단기료효우우동기방화료방안 ,불량반응저 ,환자내수량호 ,시일충안전、유효적치료방법.
Objective To observe the clinical efficacy of microwave ablation combined with 131 I-chTNT ra-dioimmunotherapy to treat non-small cell lung cancer (NSCLC) .Methods Seventy-eight patients who were path-ologically confirmed with NSCLC were divided into two groups ,control group (37 cases) with docetaxel combined with cisplatin in the treatment ;observation group (41 cases) with CT-guided percutaneous microwave ablation combined with 131 I-chTNT radioimmunotherapy .Results The effective rate of observation group was 68% ,signif-icantly higher than 46% of the control group .The difference was statistically significant between two groups (P<0 .05) ;after treatment ,the observation group improved more obviously ,and the difference was statistically sig-nificant between two groups (P<0 .05);the side effects occurred in the observation group were significantly less than those of the control group ,and the difference was statistically significant between two groups (P<0 .05) . Conclusion The treatment of NSCLC by microwave ablation combined with 131 I-chTNT radioimmunotherapy has satisfactory clinical efficacy and reliable security .